Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.10.2019 | Case report

Docetaxel/ramucirumab

Various toxicities: 6 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Takase M, et al. Measures to ensure safety of docetaxel plus ramucirumab for advanced non-small-cell lung cancer as the second-or later-line. Gan to Kagaku Ryoho 46: 1039-1042, No. 6, Jun 2019. Available from: URL: https://www.ncbi.nlm.nih.gov/pubmed/31273171 [Japanese; summarised from a translation] - Japan Takase M, et al. Measures to ensure safety of docetaxel plus ramucirumab for advanced non-small-cell lung cancer as the second-or later-line. Gan to Kagaku Ryoho 46: 1039-1042, No. 6, Jun 2019. Available from: URL: https://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​31273171 [Japanese; summarised from a translation] - Japan
Metadaten
Titel
Docetaxel/ramucirumab
Various toxicities: 6 case reports
Publikationsdatum
01.10.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-70328-4

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Clozapine

Case report

Antineoplastics

Case report

Alemtuzumab

Case report

Methotrexate

Case report

Etoricoxib

Case report

Paclitaxel